Literature DB >> 20461750

MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.

Kaitlyn Wurz1, Rochelle L Garcia, Barbara A Goff, Patrick S Mitchell, Jun Haeng Lee, Muneesh Tewari, Elizabeth M Swisher.   

Abstract

MicroRNAs are often aberrantly expressed in human neoplasms and are postulated to play a role in neoplastic initiation and progression. miR-221 and miR-222 negatively regulate expression of CDKN1B (p27) and CDKN1C (p57), two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas. We characterized miR-221 and miR-222 expression in 49 sporadic high grade ovarian carcinomas and determined whether somatic mutation or epigenetic alterations explained the differences in expression of these miRNAs. We correlated these findings with protein expression of CDKN1B and CDKN1C as assessed by immunohistochemistry. Expression of miR-221 and miR-222 were closely correlated with each other (P = 0.0001). Interestingly, a lower ratio of miR-221 to miR-222 expression was significantly correlated with worse overall survival (P = 0.01) and remained a significant predictor of overall survival in multivariate analysis using the covariate adequacy of surgical cytoreduction (P = 0.03). Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression (P = 0.009 and 0.01). In contrast, CDKN1B expression was not associated with miR-221 or miR-222 expression. Neither somatic mutations nor methylation of the studied region explained the alterations in miR-221 and miR-222 expression in most carcinomas. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20461750      PMCID: PMC2869465          DOI: 10.1002/gcc.20768

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  23 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study.

Authors:  M Baekelandt; R Holm; C G Tropé; J M Nesland; G B Kristensen
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

3.  Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer.

Authors:  V Masciullo; A Sgambato; C Pacilio; B Pucci; G Ferrandina; J Palazzo; A Carbone; A Cittadini; S Mancuso; G Scambia; A Giordano
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

4.  Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

Authors:  E Rosenberg; R I Demopoulos; A Zeleniuch-Jacquotte; H Yee; J Sorich; J L Speyer; E W Newcomb
Journal:  Hum Pathol       Date:  2001-08       Impact factor: 3.466

5.  The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors.

Authors:  L Sui; M Tokuda; M Ohno; O Hatase; T Hando
Journal:  Gynecol Oncol       Date:  1999-05       Impact factor: 5.482

6.  Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors.

Authors:  Li Sui; Youyi Dong; Masayuki Ohno; Yasuo Watanabe; Katsuyoshi Sugimoto; Masaaki Tokuda
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

7.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

8.  Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.

Authors:  Kristin K Zorn; Amir A Jazaeri; Christopher S Awtrey; Ginger J Gardner; Samuel C Mok; Jeff Boyd; Michael J Birrer
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

Review 9.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

10.  Clustering and conservation patterns of human microRNAs.

Authors:  Yael Altuvia; Pablo Landgraf; Gila Lithwick; Naama Elefant; Sébastien Pfeffer; Alexei Aravin; Michael J Brownstein; Thomas Tuschl; Hanah Margalit
Journal:  Nucleic Acids Res       Date:  2005-05-12       Impact factor: 16.971

View more
  33 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

Review 2.  Translational application of epigenetic alterations: ovarian cancer as a model.

Authors:  Marie E Maradeo; Paul Cairns
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

Review 3.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

4.  Circulating MicroRNAs as Biomarkers in Health and Disease.

Authors:  V Kuzhandai Velu; R Ramesh; A R Srinivasan
Journal:  J Clin Diagn Res       Date:  2012-10-25

5.  Expression Profile Analysis of miR-221 and miR-222 in Different Tissues and Head Kidney Cells of Cynoglossus semilaevis, Following Pathogen Infection.

Authors:  Hui Yan; Yadong Chen; Shun Zhou; Chao Li; Guangye Gong; Xuejie Chen; Tianzi Wang; Songlin Chen; Zhenxia Sha
Journal:  Mar Biotechnol (NY)       Date:  2015-09-29       Impact factor: 3.619

Review 6.  Roles and mechanisms of microRNAs in pancreatic cancer.

Authors:  Lidong Zhang; Md Saha Jamaluddin; Sarah M Weakley; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

7.  miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling.

Authors:  Xiaojun Liu; Junjie Xiao; Han Zhu; Xin Wei; Colin Platt; Federico Damilano; Chunyang Xiao; Vassilios Bezzerides; Pontus Boström; Lin Che; Chunxiang Zhang; Bruce M Spiegelman; Anthony Rosenzweig
Journal:  Cell Metab       Date:  2015-04-07       Impact factor: 27.287

8.  Expression analysis of miR-221-3p and its target genes in horses.

Authors:  So-Won Kim; Ara Jo; Jennifer Im; Hee-Eun Lee; Heui-Soo Kim
Journal:  Genes Genomics       Date:  2019-01-02       Impact factor: 1.839

Review 9.  Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors:  Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

Review 10.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Authors:  Marta Szajnik; Małgorzata Czystowska-Kuźmicz; Esther Elishaev; Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2016-06-23       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.